Clovis Oncology Announces 2019 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Clovis Oncology (CLVS) Misses Q4 EPS by 10c
February 24, 2020 4:14 PM ESTClovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.81), $0.10 worse than the analyst estimate of ($1.71). Revenue for the quarter came in at $39.3 million versus the consensus estimate of $38.97 million.
$296.7M in cash, cash equivalents and available for sale securities at December 31, 2019; continue to... More
